Dexcom Stock News

DexCom, Inc. (NASDAQ:DXCM) insider Steven Robert Pacelli sold 250 shares of the firms stock in a transaction dated Tuesday, November 23rd. The stock was sold at an average price of $612.26, for a total transaction of $153,065.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through []

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 856 shares of the stock in a transaction dated Monday, November 22nd. The shares were sold at an average price of $638.65, for a total value of $546,684.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. []

IFM Investors Pty Ltd raised its position in DexCom, Inc. (NASDAQ:DXCM) by 0.7% during the third quarter, Holdings Channel.com reports. The firm owned 12,697 shares of the medical device companys stock after buying an additional 93 shares during the period. IFM Investors Pty Ltds holdings in DexCom were worth $6,943,000 at the end of the []

In our continuing quest to spread facts and not bullshit we thought today we would prove just how childish corporations can be. As much as wed like to think there are adults at the table when it comes to this battle between Abbott and Dexcom, The post Pennies + Nickels = Billions appeared first on Diabetic Investor .

Shares of DexCom, Inc. (NASDAQ:DXCM) have received a consensus rating of Buy from the eighteen research firms that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 1 year price objective among brokers []

Harbor Investment Advisory LLC cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 33.2% in the third quarter, HoldingsChannel reports. The firm owned 771 shares of the medical device companys stock after selling 383 shares during the quarter. Harbor Investment Advisory LLCs holdings in DexCom were worth $422,000 at the end of the most recent reporting []

New England Research & Management Inc. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 63.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 460 shares of the medical device companys stock after selling 815 shares during the period. []

DexCom, Inc. (NASDAQ:DXCM) has been given a consensus recommendation of Buy by the eighteen research firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on []

This healthcare company isn't done beating the market.

Look out for companies that can latch on to strong long-term trends to add to when the market undergoes a correction.

Abbott's the heavyweight, and DexCom is the formidable challenger.

Related Stocks: DXCM ,

Related Stocks: GOOG , GOOGL , FB , NVDA , ABT , ANGL , JCI , ORCL , INTU , BDC , DXCM , CMCSA , GM , CSCO , CRSP , TDOC , AIG , CDNA ,

The Diabetes Monitors Market research report incorporates an in generally speaking all around assessment, for example, market drivers, openings, constraints, most recent turns of events and models, division of the market, savage appraisal, by and large correspondingly as local assessment